Lilly licenses Alchemab’s ALS antibody ATLX-1282 in $415mn deal, expanding its neuroscience pipeline with a novel, ...

Recursion Pharmaceuticals has narrowed its drug development pipeline as it seeks to reduce costs and reprioritise resources.

Veeva Commercial Summit is one of the largest industry events in North America for commercial and medical affairs leaders.

Three Motley Fool contributors think they've found no-brainer healthcare stocks to buy in May. Here's why they picked Eli ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Intuitive secured a single port robot clearance, Resmed bought sleep testing facility Virtuox, and Precision Neuroscience ...

CVS Caremark has selected Novo Nordisk’s Wegovy as the preferred GLP-1 medication for its largest commercial template formularies, effective July 1. In March, Novo Nordisk launched NovoCare Pharmacy ...

The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion deal to develop Danish ...

Eli Lilly (LLY) has enjoyed a successful run the past several quarters as the company's blockbuster GLP-1 weight-loss drug ...

Starting July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial template ...

Eli Lilly’s LLY first-quarter revenue grew 45%, as combined sales for Mounjaro (diabetes) and Zepbound (obesity) rose ...